Bayer Aktiengesellschaft

Klaus Schlossmann

Siegfried Goldmann

Hilmar Bischoff

Walter Puls

Dieter Petzinna

Friedrich Bossert

Joachim Bender

Elisabeth Perzborn

Stanislav Kazda

Friedel Seuter

Mithat Mardin

Volker Fiedler

Dieter Mayer

Wulf Vater

Egbert Wehinger

Kurt Stoepel

Robertson Towart

Arend Heise

Friedrich Hoffmeister

Wolf-Dieter Busse

Horst Meyer

Bernd Klinksiek

Peter Serno

Alfred Zembrod

Hans J Ahr

Hans-Jurgen Ahr

Novel blood sugar-lowering dihydropyridinelactones of the formula ##STR1## in which R represents halogen, C.sub.1 -C.sub.10 -alkyl, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.10 -alkylthio, C.sub.1 -C.sub.10 -alkylsulphinyl, C.sub.1 -C.sub.10 -alkylsulphonyl, cyano, C.sub.1 -C.sub.6 - mono- or polyfluoroalkyl, C.sub.1 -C.sub.6 -mono- or polyfluoroalkoxy or nitro,

Novel 1-alkyl-substituted 1,4-dihydropyridinelactone anti-diabetics

In the parenteral administration of a dihydropyridine, the improvement which comprises administering the dihydropyridine in an aqueous medium of pH 3 to 8.5 having dispersed therein liposomes with an average diameter of 20-1000 nm, the liposome membrane containng the following constituents by weight:

Medicament formulation containing dihydropyridines and a process for its

Blood sugar levels are reduced by administration of novel 4-thienyl-dihydropyridines of the formula ##STR1## in which R.sup.1 represents 1 or 2 halogen atoms, or represents straight-chain, branched or cyclic alkyl with up to 8 carbon atoms,

Lowering blood sugar with novel 4-thienyl-dihydropyridines

Certain 4-thienyl-dihydropyridines

Blood-sugar-lowering dihydropyridines of the formula ##STR1## in which R.sup.1 represents phenyl, naphthyl, thienyl, pyridyl, chromenyl or thiochromenyl, it being possible for the radicals mentioned each to carry up to 2 identical or different substituents from the series comprising halogen, alkyl, alkoxy and alkylthio with in each case up to 6 carbon atoms, fluoroalkyl and fluoroalkoxy with in each case up to 3 carbon atoms and 3 fluorine atoms, nitro and cyano,

Dihydropyridine compounds and their use in reducing blood sugar

Reducing blood sugar with the novel dihydropyridinelactols, or salts thereof, of the formula ##STR1## in which R.sup.1 represents a phenyl, naphthyl, thienyl, pyridyl, chromonyl, thiochromonyl or thiochromenyl radical, the stated radicals optionally containing 1 or 2 identical or different substituents from the group consisting of fluorine, chlorine and bromine, alkyl, alkoxy and alkylthio, each having 1 to 6 carbon atoms, and fluoroalkyl or fluoroalkoxy, each having up to 3 carbon atoms and 3 fluorine atoms, and nitro and cyano,

Dihydropyridinelactols and their use as medicaments which influence

A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of ischaemias and disorders in cardiac rhythm, inflammations of the skin and the eye, and of rheumatic, allergic and asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, shock lung, oxygen intoxications and ulcerations which comprises administering to such patient an effective amount of a compound of the formula ##STR1## wherein R represents an aryl or heteroaryl radical which has 6 to 12 C atoms and optionally contains 1 to 3 identical or different substituents from the group comprising halogen, trifluoromethyl, alkyl, alkenyl, alkoxy, alkylamino, cyano, trifluoromethoxy, nitro, hydroxyl, SO.sub.n -alkyl (n=0 to 2) or SO.sub.n -trifluoromethyl (n=0 to 2), alkyl, alkenyl and alkoxy in each case being understood as meaning radicals with 1 to 4 C atoms,

Inhibiting lipoxygenase with pyrazolone derivatives

A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of ischaemias and disorders in cardiac rhythm and of rheumatic, allergic and asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, oxygen intoxications and ulcerations which comprises administering to such patient an effective amount of nafazatrom.

Nafazatrom as a lipoxygenase inhibitor

The present invention provides 1,4-dihydropyridine derivatives of the formula in which ##STR1## R represents hydrogen, alkyl, alkenyl, alkoxyalkyl, aryl or aralkyl, the alkyl and aryl groups being optionally substituted,

1,4-Dihydropyridine derivatives substituted in the 2 position, and their

The invention includes the provision of 2-alkyleneaminodihydropyridines and salts thereof and are useful, inter alia, as coronary dilators and antihypertensive agents. Also included in the invention are pharmaceutical compositions containing said 2-alkyleneaminodihydropyridines and methods of treatment involving the use of said compounds or compositions.

2-Alkyleneaminodihydropyridines compounds, their production and their

Growing community of inventors

Wuppertal, Germany

Klaus Schlossmann